Latest Partnerships News

Alpha HPA Limited has reached a major funding milestone with a $400 million senior debt package for its HPA First Project Stage 2, while experiencing accelerating demand from the semiconductor sector and advancing new product developments.

Neurotech International reports key clinical progress in paediatric neurological disorders, securing FDA orphan drug designation for its Rett Syndrome treatment and advancing pivotal trials for ASD and PANDAS/PANS.

Lion Energy Limited reports significant progress in its green hydrogen project at Port of Brisbane and confirms major oil and gas prospects in Indonesia, setting the stage for future drilling and commercial development.

Cokal Limited has partnered with Cratus Group to establish an Infrastructure Joint Venture aimed at significantly expanding coal transport capacity and efficiency, supporting a ramp-up in metallurgical coal production at the BBM mine.

Victory Metals advances its North Stanmore Heavy Rare Earth Project with a strategic offtake MOU signed with Sumitomo Corporation and a significant upgrade to its mineral resource estimate, reinforcing its position in the critical rare earths sector.

Anax Metals has confirmed the success of its scaled-up bioleaching technology, achieving copper recoveries of up to 80% and zinc recoveries exceeding 90%, reinforcing its strategic position in Pilbara's base metals sector.

I Synergy Group Limited has successfully completed a $100,000 private placement at a 16.67% discount, aiming to bolster its growth and working capital. The move signals investor confidence as the technology company advances its digital solutions agenda.

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.

Galan Lithium Limited has announced a substantial 150% increase in its Candelas Mineral Resource to 1.6 Mt LCE, lifting its total Hombre Muerto West resource to 9.5 Mt LCE and securing a spot among the world’s top 10 lithium projects.

CurveBeam AI Limited reported a remarkable 150% increase in device purchase orders in Q2 FY25, driven by strong demand for its HiRise™M platform and a new commercial agreement with Stryker. The company is advancing validation of its Enhanced HiRise™ for robotic surgical systems, despite a regulatory delay for its BMD SaaS module.

Algorae Pharmaceuticals reports robust progress in its drug development pipeline, highlighted by promising preclinical results for cardiovascular and dementia candidates and significant AI platform enhancements.

CurveBeam AI has reported a record quarter for HiRise™ device purchase orders, driven by a strategic expansion with Stryker in Australia and New Zealand. The company also advanced its FDA regulatory pathway for its BMD module, setting sights on mid-2025 submission.